微波消融与冷冻消融治疗肾细胞癌的比较:系统文献综述与Meta分析
该系统综述与Meta分析纳入2006年1月至2022年2月发表的英文研究,比较微波消融(MWA)与冷冻消融治疗原发性肾细胞癌(RCC)的疗效与安全性。MWA组与冷冻消融组基线特征相似,平均肿瘤大小分别为2.74 cm和2.69 cm。MWA的消融时间显著短于冷冻消融(加权均数差24.55分钟,95%CI -31.71至-17.38,P<.0001),1年局部肿瘤复发(LTR)显著低于冷冻消融(OR 0.33,95%CI 0.10-0.93,P=.04),其他结局无显著差异。
要点
- MWA消融时间显著短于冷冻消融,加权均数差24.55分钟(95%CI -31.71至-17.38,P<.0001)。
- MWA的1年局部肿瘤复发显著低于冷冻消融(OR 0.33,95%CI 0.10-0.93,P=.04)。
- 其他结局在MWA与冷冻消融间无显著差异,MWA治疗原发性RCC与冷冻消融同样安全有效,尚需未来比较研究证实。
核心结论
- 对于RCC患者,MWA相比冷冻消融显著改善1年LTR和消融时间,其他结局相似或倾向于MWA但无统计学显著性,MWA与冷冻消融同样安全有效,尚需未来比较研究证实。
研究设计与样本
- 系统检索MEDLINE、Embase和Cochrane数据库,纳入2006年1月至2022年2月发表的英文研究,对象为接受MWA或冷冻消融的成人原发性RCC,纳入RCT、比较观察性研究和单臂研究的 study arms。
- 采用随机效应模型进行单臂Meta分析,并排除MINORs量表评估的低质量研究进行敏感性分析,采用单变量和多变量分析评估预后因素。
主要发现
- MWA与冷冻消融基线特征相似,平均肿瘤大小分别为2.74 cm和2.69 cm。
- 消融时间MWA显著短于冷冻消融,Meta回归加权均数差24.55分钟(95%CI -31.71至-17.38,P<.0001)。
- 1年LTR MWA显著低于冷冻消融(OR 0.33,95%CI 0.10-0.93,P=.04)。
- 其他结局在MWA与冷冻消融间无显著差异。
关键数值与推荐
- 1年局部肿瘤复发:MWA vs 冷冻消融 OR 0.33(95%CI 0.10-0.93,P=.04),MWA较低。
- 消融时间:MWA vs 冷冻消融加权均数差24.55分钟(95%CI -31.71至-17.38,P<.0001),MWA较短。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a systematic review and meta-analysis comparing microwave ablation (MWA) and cryoablation for renal cell carcinoma (RCC). METHODS: The systematic search was performed in MEDLINE, Embase, and Cochrane databases. Studies published in English from January 2006 to February 2022 that assessed adults with primary RCC who received MWA or cryoablation were included. Study arms from RCTs, comparative observational, and single-arm studies were eligible. The outcomes included local tumor recurrence (LTR), overall survival, disease-free survival, overall/major complications, procedure/ablation time, 1- to 3-month primary technique efficacy, and technical success. Single-arm meta-analyses were performed using the random effects model. Sensitivity analyses excluding low-quality studies assessed using the MINORs scale were performed. Univariable and multivariable examined the effects of prognostic factors. RESULTS: Baseline characteristics were similar between groups and mean tumor size for MWA and cryoablation were 2.74 and 2.69 cm. Single-arm meta-analyses were similar for LTR and secondary outcomes between cryoablation and MWA. Ablation time was significantly shorter with MWA than with cryoablation (meta-regression weighted mean difference 24.55 minutes, 95% confidence interval -31.71, -17.38, P < .0001). One-year LTR was significantly lower with MWA than cryoablation (odds ratio 0.33, 95% confidence interval 0.10-0.93, P = .04). There were no significant differences for other outcomes. CONCLUSION: MWA provides significantly improved 1-year LTR and ablation time compared with cryoablation for patients with RCC. Other outcomes appeared similar or favorable for MWA; however, results were not statistically significant. MWA of primary RCC is as safe and effective as cryoablation, which should be confirmed with future comparative studies.
引用
- McClure T, Lansing A, Ferko N, et al. A Comparison of Microwave Ablation and Cryoablation for the Treatment of Renal Cell Carcinoma: A Systematic Literature Review and Meta-analysis. Urology. 2023. PMID: 37331485. doi:10.1016/j.urology.2023.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。